We’re excited to introduce our work demonstrating that biologics called “decoy” vesicles can inhibit SARS-CoV-2 infection and are robust to multiple problematic viral mutations. Congratulations to Taylor and Devin, and our excellent collaborator Dr. Neha Kamat. We hope that the engineering insights identified in this study will accelerate the development of this exciting new class of antiviral therapeutics (for COVID-19 and/or other diseases). Check out the preprint here!
